Your test is perfect? Color me skeptical.
"Have curious conversation; don't cross-examine."
"Please respond to the strongest plausible interpretation of what someone says, not a weaker one that's easier to criticize. Assume good faith."
> Our initial data show no false-positives and no false-negatives out of all specimens assayed.
Is:
> the false result rate [of the test] is low
While you originally responded to the statement from the OP with:
> [You're saying that] your test is perfect? Color me skeptical.
Such tests are immediately of very high value because they allow us to understand immunity to Covid-19, and to actually validate the estimates of cases amongst those who haven’t sought treatment.
These are both of huge value regardless of the percentage of the US population estimate to have previously contracted Covid-19.
By all means market your test which seems like an awesome contribution, but please don’t do so by devaluing other important tools.
[edit: the parent post has been edited to be less dismissive without acknowledgement since I made this comment]
[edit: looks like I’m wrong about the post being edited. Sorry for that. I stand by everything else I say here:
Serological tests are useful and needed right now, not at some future stage. It’s not hard to google to verify this, and it’s irresponsible to downplay the value of a test we need now.]
By the way, as a company, we really don't have much to gain from this test. If it does not get adopted, we'll go back to building our core business which has been growing 100% quarter over quarter. We have poured resources into the current development, because it is the right thing to do. No investor in our Series B round will take into account any non-recurring sell-almost-at-cost revenues that we get from a once-in-a-century pandemic.
This is not so. They are valuable right now.
https://www.newscientist.com/article/mg24532754-600-can-you-...
https://www.ksbw.com/article/new-study-investigates-californ...
If only 1% are infected, and the false positive rate is 1%, it's quite hard to determine what the test result actually means. On the other hand, some places like New York City are already at 0.7% per-capita known positives, and they're not even able to test everyone with symptoms. Their true infection rate could very well be 10%, which serological testing could confirm.
It takes about a month before an antibody test is accurate in someone who has had a virus, so using them now would only detect cases where the person had the virus in early March. That limits the value of serological testing considerably.
This is only true for the IgG class of antibodies; we typically see the IgM class of antibodies arise within 5-7 days of infection.
You are generally correct, however, in stating that antibody tests have a window in which they cannot detect a new infection.
This is a test to see if someone has a current COVID-19 infection. The antibody tests (serological) tests are also important, but since it is estimated that only ~1% of the US has previously contracted COVID-19, it will be a while before serological testing becomes useful at a population level.
Our initial data show no false-positives and no false-negatives out of all specimens assayed. However, it is early days still and none of the leading tests have real-world data on false-positive and false-negative rates. The crucial parameter here to compare test performance is limit of detection (LOD). We showed we could detect as few as 10 molecules of virus, which is on par with the best RT-qPCR tests.
Cost is definitely an important consideration for roll-out of a widespread test. We anticipate that the cost will be about $15 per test.